Johns Hopkins HIV Guide
Ganciclovir
INDICATIONS
FDA
FDA
Systemic
- Treatment of CMV retinitis (IV) in immunocompromised patients.
- Prophylaxis and prevention of CMV disease recurrence in pts with AIDS and solid organ transplant recipients
- Treatment and prevention of CMV disease in immunocompromised patients; oral valganciclovir is preferred whenever oral therapy is feasible.
- Use for primary prophylaxis in HIV is FDA approved but not currently recommended; valganciclovir is preferred.
Topical
- Herpes keratitis (ophthalmic gel)
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- Castleman’s disease (limited data)
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: August 7, 2026
Citation
Soto, Caitlin, and Kathryn Dzintars. "Ganciclovir." Johns Hopkins HIV Guide, The Johns Hopkins University, 2026. Johns Hopkins Guides, www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545262/all/Ganciclovir.
Soto C, Dzintars K. Ganciclovir. Johns Hopkins HIV Guide. The Johns Hopkins University; 2026. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545262/all/Ganciclovir. Accessed August 12, 2026.
Soto, C., & Dzintars, K. (2026). Ganciclovir. In Johns Hopkins HIV Guide. The Johns Hopkins University. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545262/all/Ganciclovir
Soto C, Dzintars K. Ganciclovir [Internet]. In: Johns Hopkins HIV Guide. The Johns Hopkins University; 2026. [cited 2026 August 12]. Available from: https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545262/all/Ganciclovir.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Ganciclovir
ID - 545262
A1 - Soto,Caitlin,PharmD, BCIDP
AU - Dzintars,Kathryn,Pharm.D. BCPS
Y1 - 2026/08/07/
BT - Johns Hopkins HIV Guide
UR - https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545262/all/Ganciclovir
PB - The Johns Hopkins University
DB - Johns Hopkins Guides
DP - Unbound Medicine
ER -
